Tag Archives: companion diagnostics

November, 2018

28 November
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test

TOKYO and MUNICH and BASKING RIDGE, N.J., Nov. 27, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into an agreement with Roche to collaborate on the development of a new HER2 low companion diagnostic test. Under the terms of the agreement, Roche …
Share

12 September
Incyte and Foundation Medicine Partner to Develop Companion Diagnostic for Pemigatinib in Patients with Cholangiocarcinoma

WILMINGTON, Del. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Incyte Corporation (NASDAQ:INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx development for pemigatinib (INCB54828), Incyte’s selective FGFR1/2/3 inhibitor, in patients with …
Share

24 May
Foundation Medicine and Merck Enter Immuno-Oncology Companion Diagnostics Collaboration

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop companion diagnostic tests for use with KEYTRUDA®(pembrolizumab), Merck’s anti-PD-1 therapy and the first approved immunotherapy for microsatellite instability (MSI) high or mismatch repair deficient solid tumors. The companion …
Share

3 May
Foundation Medicine and AstraZeneca Partner to Develop Companion Diagnostic Assays in Oncology

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced an agreement with AstraZeneca to develop companion diagnostic assays to facilitate personalized medicine in oncology by identifying patients most likely to benefit from medicines within AstraZeneca’s oncology pipeline. “We use companion diagnostics throughout clinical development to deliver innovative, targeted therapies to patients …
Share

4 January
Pfizer Partners with KineMed for Development of Kinetic Biomarkers

SAN FRANCISCO–(BUSINESS WIRE)–KineMed Inc. today announced that it has entered into a strategic collaboration with Pfizer Inc. (NYSE:PFE) to discover and develop novel proprietary biomarkers in various fields of unmet medical need. KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilizing mass spectroscopy and stable …
Share

20 May
Celgene to Use Cypher’s Technology to Discover Genomic Biomarkers

Genome informatics company Cypher Genomics, Inc. will use its diagnostics technology to assist Celgene in discovering novel genomic biomarkers that identify patients who respond well to specific drugs. The collaboration comes during industry’s push in increasing efforts in precision medicine, tailoring therapy based on a patient’s genetic makeup. The companies announced …
Share